GSK’s Injectable HIV Drug Bests Pills in Patients with Medication Adherence Issues

HIV-focused biotech ViiV Healthcare, which is majority owned by GSK, on Wednesday posted interim findings from the Phase III LATITUDE trial demonstrating that its long-acting injectable HIV drug Cabenuva (cabotegravir plus rilpivirine) is better than oral daily antiretroviral treatment in patients who have trouble sticking to their medication schedule.